- Home
- NWG vs TAK Comparison
NWG vs TAK Comparison
Compare NWG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWG | TAK |
|---|---|---|
| Founded | 1727 | 1781 |
| Country | United Kingdom | Japan |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.6B | 57.6B |
| IPO Year | 2011 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NWG | TAK |
|---|---|---|
| Price | $18.09 | $18.89 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 1.9M |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.57% | 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.83 | $0.16 |
| Revenue Next Year | $7.43 | $1.22 |
| P/E Ratio | ★ $18.92 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $12.99 |
| 52 Week High | $19.42 | $19.10 |
Technical Indicators
Market Signals| Indicator | NWG | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 64.47 |
| Support Level | $17.04 | $17.95 |
| Resistance Level | $18.33 | N/A |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 2.15 | 82.50 |
Price Performance
Historical ComparisonAbout NWG NatWest Group plc (each representing two (2))
NatWest Group derives around 90% of its total income from the United Kingdom. The bank operates a retail, commercial, and private bank in the UK, offering clients lending and payment services as well as asset management services.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.